Grading of chemotherapy-induced peripheral neuropathy

Annals of Oncology

Volumn 11, Issue 5, 2000, Pages 509-513

  Postma, T J ^a   Heimans, J J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Assessment; Chemotherapy; Peripheral neuropathy

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; PACLITAXEL; VINCRISTINE;

CANCER CHEMOTHERAPY; DISEASE SEVERITY; HUMAN; NEUROTOXICITY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SCORING SYSTEM;

ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; PERIPHERAL NERVOUS SYSTEM DISEASES; QUALITY OF LIFE; REFERENCE VALUES; SEVERITY OF ILLNESS INDEX;

EID: 0033946726     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008345613594     Document Type: Review

References (50)

1. Riaz SS, Tomlinson DR. Neurotrophic factors in peripheral neuropathies: Pharmacological strategies. Prog Neurobiol 1996; 49: 125-43.
2. Dyck PJ. Davies JL, Litchey WJ, O'Brien PC. Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study cohort. Neurology 1997; 49: 229-39.
3. Postma TJ, Heimans JJ. Chemotherapy-induced peripheral neuropathy. In Vinkcn PJ, Bruyn GW (eds), Vecht CJ (vol. ed): Handbook of Clinical Neurology, Vol 69 (rev. series 25). Neuro-Oncology. Part III. Neurological Disorders in Systemic Cancer. Amsterdam, Elsevier Science 1997; 459-79.
4. Siegal T, Haim N. Cisplatin-induced peripheral neuropathy. Frequent off-therapy deterioration, demyelinating syndromes, and muscle cramps. Cancer 1990; 66: 1117-23.
5. Markman M. Chemotherapy-associated neurotoxicity: An important side effect-impacting on quality, rather than quantity, of life. J Cancer Res Clin Oncol 1996; 122: 511-2.
6. Schiller JH, Storer B, Tutsch K et al. Phase I trial of three-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer. J Clin Oncol 1994; 12: 241-8.
7. Chaudry V, Rowinsky EK, Sartorius SE et al. Peripheral neuropathy from taxol and cisplatin combination chemotherapy: Clinical and electrophysiological studies. Neurology 1994; 35: 304-11.
8. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-14.
9. Oken MM, Creech RH, Tormey DC et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-55.
10. Ajani JA, Welch SR, Raber MN et al. Comprehensive criteria for assessing therapy-induced toxicity. Cancer Invest 1990; 8: 147-59.
11. Vantongelen K. A Practical Guide to EORTC Studies. Brussels 1994.
12. Maser RE, Nielsen VK, Bass EB et al. Measuring diabetic neuropathy. Assessment and comparison of clinical examination and quantitative sensory testing. Diabetes Care 1989; 12: 270-5.
13. Brundage MD, Pater JL, Zee B. Assessing the reliability of two toxicity scales: Implications for interpreting toxicity data. J Natl Cancer Inst 1993; 85: 1138-48.
14. Postma TJ, Heimans JJ, Muller MJ et al. Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy. Ann Oncol 1998; 9: 739-44.
15. Gerritsen van der Hoop R, Vecht CJ, van der Burg MEL et al. Prevention of cisplatin neurotoxicity with an ACTH(4-9) analogue in patients with ovarian cancer. N Engl J Med 1990; 322: 89-94.
16. DeAngelis LM, Gnecco C, Taylor L, Warrell RP. Evolution of neuropathy and myopathy during intensive vincristine/corticosteroid chemotherapy for non-Hodgkin's lymphoma. Cancer 1991; 67: 2241-6.
17. Cascinu S, Cordelia L, Del Ferro E et al. Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: A randomized double-blind placebo-controlled trial. J Clin Oncol 1995; 13: 26-32.
18. Bogliun G, Marzorati L, Marzola M et al. Neurotoxicity of cisplatin ± reduced glulathione in the first-line treatment of advanced ovarian cancer. Int J Gynecol Cancer 1996; 6: 415-9.
19. Postma TJ, Vermorken JB, Liefting AJM et al. Paclitaxel-induced neuropathy. Ann Oncol 1995; 6: 489-94.
20. Roberts JA, Jenison EL, Kim K. et al. A randomized, multicenter, double-blind, placebo-controlled, dose-finding study of ORG 2766 in the prevention or delay of cisplatin-induced neuropathies in women with ovarian cancer. Gynecol Oncol 1997; 67: 172-7.
21. Berger T, Malayeri R, Doppelbauer A et al. Neurological monitoring of neurotoxicity induced by paclitaxel-cisplatin chemotherapy. Eur J Cancer 1997; 33: 1393-9.
22. Dyck PJ, Sherman WR, Hallcher LM et al. Human diabetic endoneurial sorbitol, fructose, and myo-inositol related to sural nerve morphometry. Ann Neurol 1980; 8: 590-6.
23. Dyck PJ, Karnes J, O'Brien PC, Swanson CJ. Neuropathy Symptom Profile in health, motor neuron disease, diabetic neuropathy, and amyloidosis. Neurology 1986; 36: 1300-8.
24. Dyck PJ. Quantitative sensory testing. A consensus report from the peripheral neuropathy association. Neurology 1993; 43: 1050-2.
25. Proceedings of a consensus development conference on standardized measures in diabetic neuropathy. Neurology 1992; 42: 1823-39.
26. Dyck PJ, Dyck PJB, Kennedy WR et al. Limitations of quantitative sensory testing when patients are biased toward a bad outcome. Neurology 1998; 50: 1213.
27. Casey EB, Jelliffe AM, Le Quesne PM, Millett YL. Vincristine neuropathy. Clinical and electrophysiological observations. Brain 1973; 96: 69-86.
28. Roelofs RI, Hrushesky W, Rogin J, Rosenberg L. Peripheral sensory neuropathy and cisplatin chemotherapy. Neurology 1984; 34: 934-8.
29. Riggs JE, Ashraf M, Snyder RD, Gutmann L. Prospective nerve conduction studies in cisplatin therapy. Ann Neurol 1988; 23: 92-4.
30. Elderson A, Gerritsen van der Hoop R, Haanstra W et al. Vibration perception and thermoperception as quantitative measurements in the monitoring of cisplatin induced neurotoxicity. J Neurol Sci 1989; 93: 167-74.
31. Lipton RB, Apfel SC, Dutcher JP et al. Taxol produces a predominantly sensory neuropathy. Neurology 1989; 39: 368-73.
32. LoMonaco M, Milone M, Batocchi AP et al. Cisplatin neuropathy: Clinical course and neurophysiological findings. J Neurol 1992; 239: 199-204.
33. Krarup-Hansen A, Fugleholm K, Helweg-Larsen S et al. Examination of distal involvement in cisplatin-induced neuropathy in man. Brain 1993; 116: 1017-41.
34. Forsyth PA, Balmaceda C, Peterson K et al. Prospective study of paclitaxel-induced peripheral neuropathy with quantitative sensory testing. J Neurooncol 1997; 35: 47-53.
35. Slevin ML, Plant H, Lynch D et al. Who should measure quality of life, the doctor or the patient? Br J Cancer 1988; 57: 109-12.
36. Stephens RJ, Hopwood P, Girling DJ, Machin D. Randomized trials with quality of life endpoints: Are doctors' ratings of patients' physical symptoms interchangeable with patients' self-ratings? Qual Life Res 1997; 6: 225-36.
37. Gill TM, Feinstein AR. A critical appraisal of the quality of quality-of-life measurements. JAMA 1994; 272: 619-26.
38. Quality of life and clinical trials. Lancet 1995; 346: 1-2 (Editorial).
39. O'Boyle CA, Waldron D. Quality of life issues in palliative medicine. J Neurol 1997; 244 (Suppl 4): S18-25.
40. Devinsky O. Outcome research in neurology: Incorporating health-related quality of life. Ann Neurol 1995; 37: 141-2 (Editorial).
41. Aaronson NK, Ahmedzai S. Bergman B et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality of life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365-76.
42. Cella DF, Tulsky DS, Gray G et al. The functional assessment of cancer therapy scale: Development and validation of the general measure. J Clin Oneol 1993; 11: 570-9.
43. Bergman B, Aaronson NK, Ahmedzai S et al. The EORTC QLQ-LC13: A modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trials. Eur J Cancer 1994; 30A: 635-42.
44. Sprangers MAG, Groenvold M, Arraras JI et al. The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: First results from a three-country field study. J Clin Oncol 1996; 14: 2756-68.
45. Osoba D, Aaronson NK, Muller M et al. The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires. Qual Life Res 1996; 5: 139-50.
46. Weitzner MA, Meyers CA, Gelke CK et al. The Functional Assessment of Cancer Therapy (FACT) scale. Development of a brain subscale and revalidation of the general version (FACT-G) in patients with primary brain tumors. Cancer 1995; 75: 1151-61.
47. Cull AM. Cancer-specific quality of life questionnaires: The state of the art in Europe. Eur J Cancer 1997; 33 (Suppl 6): S3-7.
48. Postma TJ, Heimans JJ, Aaronson NK et al. The impact of chemotherapy-induced peripheral neuropathy on quality of life. J Neurol Neurosurg Psychiatry 1999; 67: 838-9 (Abstr).
49. Sprangers MAG, Cull A, Bjordal K et al. The European Organization tor Research and Treatment of Cancer approach to quality of life assessment: Guidelines for developing questionnaire modules. Qual Life Res 1993; 2: 287-95.
50. Hensley ML, Schuchter LM, Lindley C et al. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol 1999; 17: 3333-55.